Opportunity Information: Apply for PA 13 315
Apply for PA 13 315
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Aug 6, 2013 and posted on Aug 6, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Public housing authorities/Indian housing authorities Small businesses Public and State controlled institutions of higher education County governments Special district governments Private institutions of higher education City or township governments Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) State governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) opportunity (Funding Opportunity Number PA 13 315) is a National Institutes of Health discretionary grant designed to spark early stage, high-impact research on primary immunodeficiency diseases. It uses the NIH R21 mechanism, which is typically intended for innovative, exploratory, or proof-of-concept projects that may be too preliminary for larger, longer-term awards. In this case, the FOA targets studies that can open new directions in understanding, detecting, and treating primary immunodeficiencies, with an emphasis on work that directly leverages human specimens or strengthens the field through improved animal modeling.
The scientific focus centers on innovative exploratory/developmental investigations in primary immunodeficiency diseases, specifically highlighting two major lanes of work. The first is ex vivo research using human specimens, meaning studies performed outside the body on patient-derived materials such as blood cells, tissues, or other clinical samples to probe immune function, pathways, or disease mechanisms in a way that stays close to human biology. The second lane is research using existing or newly developed animal models, including efforts to create or refine models that better mirror human primary immunodeficiency conditions. Alongside these approaches, the FOA explicitly encourages novel clinical strategies aimed at improving detection and identification of these disorders, uncovering the molecular basis underlying disease, or moving toward innovative therapies. In practical terms, this can include approaches such as developing new diagnostic concepts, validating emerging biomarkers, testing mechanistic hypotheses in model systems, or establishing early evidence for therapeutic strategies that could later be advanced through more extensive translational or clinical development.
A notable programmatic intent is workforce and field development: investigators who have not previously received independent NIH funding, or who have not received independent NIH funding in this particular field, are encouraged to apply. This signals an interest in bringing fresh perspectives and new entrants into primary immunodeficiency research, and in supporting projects that might be novel or unconventional but scientifically compelling.
From an administrative standpoint, this is a grant (Funding Instrument Type: Grant) under the broad NIH health research activity area. It is associated with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The award ceiling listed is $200,000, and there is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of the award.
Eligibility is broad and includes many types of U.S.-based organizations across the public, private, nonprofit, and educational sectors. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including 501(c)(3) organizations and nonprofits without 501(c)(3) status, excluding institutions of higher education in those categories), for-profit organizations (including small businesses and other for-profit entities), and a range of government bodies such as state governments, county governments, city or township governments, special district governments, and independent school districts. Tribal and community-focused entities are also included, such as federally recognized Native American tribal governments and other tribal organizations, tribally controlled colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, and Asian American Native American Pacific Islander Serving Institutions. Faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies are also listed as eligible applicants. At the same time, non-U.S. entities (foreign institutions) are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. However, the FOA allows foreign components as defined by the NIH Grants Policy Statement, which generally means a U.S. applicant organization may include certain foreign collaborations or activities when justified and compliant with NIH policy.
Timing details indicate the FOA was posted and created on August 6, 2013, with an original and current closing date of September 7, 2016, and an archive date of October 8, 2016, meaning this particular announcement is no longer active for new submissions under that posting. The full announcement was available through NIH at http://grants.nih.gov/grants/guide/pa-files/PA-13-315.html. For technical issues accessing or linking to the announcement, the provided contact was the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, this FOA aimed to fund early, creative research that advances how primary immunodeficiency diseases are modeled, understood at a molecular and functional level, detected in clinical contexts, and ultimately treated, while also lowering barriers for investigators who are new to independent NIH funding or new to this specific research area.
FAQs: Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) (PA-13-315)
What is the PA-13-315 funding opportunity?
PA-13-315 is an NIH discretionary grant funding opportunity titled "Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)." It was designed to spark early-stage, high-impact research on primary immunodeficiency diseases using the NIH R21 mechanism.
Which grant mechanism does this opportunity use?
This opportunity uses the NIH R21 mechanism, which is typically intended for innovative, exploratory, or proof-of-concept projects that may be too preliminary for larger, longer-term awards.
What is the main purpose of this R21 FOA?
The FOA aims to support early, creative research that can open new directions in understanding, detecting, and treating primary immunodeficiency diseases. It emphasizes projects that either directly leverage human specimens or strengthen the field through improved animal modeling.
What scientific areas does the FOA focus on?
The scientific focus is on innovative exploratory/developmental investigations in primary immunodeficiency diseases, with emphasis on (1) ex vivo research using human specimens and (2) research using existing or newly developed animal models.
What does "ex vivo research using human specimens" mean in this FOA?
In this context, ex vivo research refers to studies performed outside the body on patient-derived materials such as blood cells, tissues, or other clinical samples, to probe immune function, pathways, or disease mechanisms in a way that stays close to human biology.
What kinds of animal model work are encouraged?
The FOA encourages research using existing or newly developed animal models, including efforts to create or refine models that better mirror human primary immunodeficiency conditions.
Does the FOA encourage clinical detection or diagnostic strategy development?
Yes. The FOA explicitly encourages novel clinical strategies aimed at improving detection and identification of primary immunodeficiency disorders, uncovering molecular bases of disease, or moving toward innovative therapies.
What are examples of project types that fit this FOA?
Examples described include developing new diagnostic concepts, validating emerging biomarkers, testing mechanistic hypotheses in model systems, and establishing early evidence for therapeutic strategies that could later be advanced through more extensive translational or clinical development.
Is this opportunity intended for early-stage or exploratory projects?
Yes. The opportunity is positioned to fund innovative, exploratory, and developmental research, including proof-of-concept work that may be too preliminary for larger awards.
Does the FOA have a workforce or field-development intent?
Yes. Investigators who have not previously received independent NIH funding, or who have not received independent NIH funding in this particular field, are encouraged to apply. This signals an intent to bring in new entrants and fresh perspectives in primary immunodeficiency research.
What is the funding instrument type?
The funding instrument type is a Grant.
What are the CFDA numbers associated with this FOA?
The FOA is associated with CFDA 93.855 (Allergy and Infectious Diseases Research) and CFDA 93.856 (Microbiology and Infectious Diseases Research).
What is the award ceiling for this opportunity?
The listed award ceiling is $200,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of the award.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S.-based organizations across public, private, nonprofit, and educational sectors, as well as various government bodies and community- or tribal-focused entities.
Are public and state-controlled institutions of higher education eligible?
Yes. Public and state-controlled institutions of higher education are listed as eligible applicants.
Are private institutions of higher education eligible?
Yes. Private institutions of higher education are listed as eligible applicants.
Are nonprofit organizations eligible?
Yes. Nonprofits are eligible, including 501(c)(3) organizations and nonprofits without 501(c)(3) status (with the FOA noting exclusions related to institutions of higher education in those nonprofit categories).
Are for-profit organizations eligible?
Yes. For-profit organizations are eligible, including small businesses and other for-profit entities.
Which government entities are eligible to apply?
Eligible government applicants include state governments, county governments, city or township governments, special district governments, and independent school districts.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are listed as eligible. Tribally controlled colleges and universities are also included.
Are minority-serving institutions included in eligibility?
Yes. The FOA lists Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, and Asian American Native American Pacific Islander Serving Institutions among eligible applicants.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are listed as eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are listed as eligible.
Are eligible federal agencies allowed to apply?
Yes. Eligible federal agencies are listed among eligible applicants.
Are non-U.S. entities (foreign institutions) eligible to apply directly?
No. Non-U.S. entities (foreign institutions) are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible.
Can the project include foreign collaborations or activities?
Yes. The FOA allows foreign components as defined by the NIH Grants Policy Statement, meaning a U.S. applicant organization may include certain foreign collaborations or activities when justified and compliant with NIH policy.
When was this FOA posted?
The FOA was posted and created on August 6, 2013.
What were the closing date and archive date?
The original and current closing date listed is September 7, 2016, and the archive date is October 8, 2016.
Is this FOA still active for new submissions?
No. Based on the closing and archive dates provided, this particular announcement is no longer active for new submissions under that posting.
Where can the full announcement be found?
The full announcement was available through NIH at: http://grants.nih.gov/grants/guide/pa-files/PA-13-315.html
Who should be contacted for technical issues accessing or linking to the announcement?
For technical issues accessing or linking to the announcement, the provided contact is the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
What kinds of research outcomes was NIH trying to advance through this FOA?
The FOA aimed to advance how primary immunodeficiency diseases are modeled, understood at molecular and functional levels, detected in clinical contexts, and ultimately treated, while lowering barriers for investigators new to independent NIH funding or new to this research area.
Browse more opportunities from the same category: Health
Next opportunity: USDA FNS DC FY 2014
Previous opportunity: Small Grants on Primary Immunodeficiency Diseases (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 315
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 315) also looked into and applied for these:
| Funding Opportunity |
|---|
| NHLBI Program Project Applications (P01) Apply for PAR 13 316 Funding Number: PAR 13 316 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition Multicenter Osteoarthritis Study (MOST) (U01) Apply for PAR 13 320 Funding Number: PAR 13 320 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Research Resource Awards (R24) Apply for PAR 13 319 Funding Number: PAR 13 319 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| DNA Sequencing Core for an Undiagnosed Diseases Network (UDN) (U01) Apply for RFA RM 13 018 Funding Number: RFA RM 13 018 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Health Care Systems Research Collaboratory Demonstration Projects for Pragmatic Clinical Trials Focusing on Multiple Chronic Conditions (UH2/UH3) Apply for RFA RM 13 012 Funding Number: RFA RM 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Urban Indian Health 4 in 1 Program Apply for HHS 2013 IHS UIHP 0002 Funding Number: HHS 2013 IHS UIHP 0002 Agency: Indian Health Service Category: Health Funding Amount: $153,126 |
| Human Cell Reprogramming for Functional Genetics of Alzheimers Disease (R01) Apply for RFA AG 14 012 Funding Number: RFA AG 14 012 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Research to Improve the Care of Persons at Clinical High Risk for Psychotic Disorders (Collaborative R01) Apply for RFA MH 14 210 Funding Number: RFA MH 14 210 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research to Improve the Care of Persons at Clinical High Risk for Psychotic Disorders (R01) Apply for RFA MH 14 211 Funding Number: RFA MH 14 211 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research to Improve the Care of Persons at Clinical High Risk for Psychotic Disorders (R34) Apply for RFA MH 14 212 Funding Number: RFA MH 14 212 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| PPHF 2013 Immunization Increasing Human Papillomavirus (HPV) Vaccination Coverage Rates among Adolescents financed solely by 2013 Prevention and Public Health Funds Apply for CDC RFA IP13 130101PPHF13 Funding Number: CDC RFA IP13 130101PPHF13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Methods for Prevention Packages Program III (MP3 III) (R01) Apply for PAR 13 322 Funding Number: PAR 13 322 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| IIS Sentinel Site Pandemic Preparedness and Response Planning Apply for CDC RFA IP13 130201SUPP13 Funding Number: CDC RFA IP13 130201SUPP13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| 2014 NIH Pioneer Award Program (DP1) Apply for RFA RM 13 006 Funding Number: RFA RM 13 006 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| 2014 NIH Directors New Innovator Award Program (DP2) Apply for RFA RM 13 007 Funding Number: RFA RM 13 007 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Limited Pilot for NIGMS Legacy Community Wide Scientific Resources (R24) Apply for PAR 13 324 Funding Number: PAR 13 324 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grants for Early Medical/Surgical Specialists Transition to Aging Research (GEMSSTAR) (R03) Apply for RFA AG 14 010 Funding Number: RFA AG 14 010 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| NIA Revision and Resubmission Program Project Applications (P01) Apply for PAR 13 329 Funding Number: PAR 13 329 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Audacious Goals Initiative High Priority Research Area Intersection of Aging and Biological Mechanisms of Eye Disease (R01) Apply for PA 13 332 Funding Number: PA 13 332 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Bridges to Baccalaureate Program (R25) Apply for PAR 13 333 Funding Number: PAR 13 333 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 315", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.